Regeneron Pharmaceuticals (REGN) ROIC: History & Chart

Name: Regeneron Pharmaceuticals, Inc. (REGN) Return on Invested Capital (ROIC) — historical time series
Creator: TGMCharts

Compare

Regeneron Pharmaceuticals, Inc.(REGN)

Biotechnology · Tarrytown, NY

$810.31+0.00 (+0.00%)

Delayed quote: Sep 8, 2026, 4:00 PM EDT

Compare

About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.

Tarrytown, NY

15,410 employees

www.regeneron.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Leonard S. Schleifer

View full financials

REGN Return on Invested Capital (ROIC) Metrics

RETURN ON INVESTED CAPITAL (ROIC)

9.19%

RETURN ON INVESTED CAPITAL (ROIC) AVG TTM

9.15%

RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y

11.18%

RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y

17.30%

RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y

15.95%

RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y

16.72%

RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y

7.92%

CURRENT VS TTM AVG

+0.42%

CURRENT VS 3Y AVG

-17.81%

CURRENT VS 5Y AVG

-46.89%

CURRENT VS 10Y AVG

-42.37%

CURRENT VS 15Y AVG

-45.05%

CURRENT VS 20Y AVG

+16.05%

SECTOR MEDIAN · HEALTHCARE

8.75%

median of 90 covered companies

CURRENT VS SECTOR MEDIAN

+5.09%

vs the sector median at left

NAME	MARKET CAP	RETURN ON INVESTED CAPITAL (ROIC)	TTM	3Y	5Y
Regeneron Pharmaceuticals, Inc. (REGN)	$83.48B	9.19%	9.15%	11.18%	17.30%
HCA Healthcare, Inc. (HCA)vs ›	$87.04B	19.41%	17.66%	17.17%	17.02%
Elevance Health Inc. (ELV)vs ›	$87.17B	6.34%	6.70%	7.11%	7.33%
Cigna Corporation (CI)vs ›	$72.89B	7.69%	7.02%	7.07%	6.51%
GSK plc (GSK)vs ›	$97.25B	13.95%	12.57%	12.55%	10.41%
Boston Scientific Corporation (BSX)vs ›	$66.86B	10.57%	7.46%	6.12%	5.55%
Sanofi (SNY)vs ›	$103.62B	5.42%	6.63%	6.62%	7.56%
Cencora, Inc. (COR)vs ›	$63.17B	12.75%	15.09%	14.58%	14.67%
McKesson Corporation (MCK)vs ›	$104.10B	28.34%	27.87%	25.19%	21.44%
Stryker Corporation (SYK)vs ›	$105.97B	9.82%	10.14%	10.34%	10.08%

NAME

MARKET CAP

RETURN ON INVESTED CAPITAL (ROIC)

TTM

Regeneron Pharmaceuticals, Inc. (REGN)

$83.48B

9.19%

9.15%

11.18%

17.30%

HCA Healthcare, Inc. (HCA)vs ›

$87.04B

19.41%

17.66%

17.17%

17.02%

Elevance Health Inc. (ELV)vs ›

$87.17B

6.34%

6.70%

7.11%

7.33%

Cigna Corporation (CI)vs ›

$72.89B

7.69%

7.02%

7.07%

6.51%

GSK plc (GSK)vs ›

$97.25B

13.95%

12.57%

12.55%

10.41%

Boston Scientific Corporation (BSX)vs ›

$66.86B

10.57%

7.46%

6.12%

5.55%

Sanofi (SNY)vs ›

$103.62B

5.42%

6.63%

6.62%

7.56%

Cencora, Inc. (COR)vs ›

$63.17B

12.75%

15.09%

14.58%

14.67%

McKesson Corporation (MCK)vs ›

$104.10B

28.34%

27.87%

25.19%

21.44%

Stryker Corporation (SYK)vs ›

$105.97B

9.82%

10.14%

10.34%

10.08%

Return on Invested Capital (ROIC) Formula & Definition

ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)

Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.

Return on Invested Capital (ROIC) FAQ

What is the return on invested capital (ROIC) for Regeneron Pharmaceuticals, Inc. (REGN)?

The return on invested capital (ROIC) for REGN stock is 9.19%.

Is Regeneron Pharmaceuticals, Inc.'s return on invested capital (ROIC) high or low?

The return on invested capital (ROIC) of 9.19% is 47% below its 5-year average of 17.30%, near the low end of its 5-year range (8.51%–36.03%).

What is the TTM average return on invested capital (ROIC) for Regeneron Pharmaceuticals, Inc. (REGN)?

The TTM average return on invested capital (ROIC) for REGN stock is 9.15%.

What is the 3Y average return on invested capital (ROIC) for Regeneron Pharmaceuticals, Inc. (REGN)?

The 3Y average return on invested capital (ROIC) for REGN stock is 11.18%.

What is the 5Y average return on invested capital (ROIC) for Regeneron Pharmaceuticals, Inc. (REGN)?

The 5Y average return on invested capital (ROIC) for REGN stock is 17.30%.

What is the 10Y average return on invested capital (ROIC) for Regeneron Pharmaceuticals, Inc. (REGN)?

The 10Y average return on invested capital (ROIC) for REGN stock is 15.95%.

What is the 15Y average return on invested capital (ROIC) for Regeneron Pharmaceuticals, Inc. (REGN)?

The 15Y average return on invested capital (ROIC) for REGN stock is 16.72%.

What is the 20Y average return on invested capital (ROIC) for Regeneron Pharmaceuticals, Inc. (REGN)?

The 20Y average return on invested capital (ROIC) for REGN stock is 7.92%.

DATE	RETURN ON INVESTED CAPITAL (ROIC)
2026-06-30	9.19%
2026-03-31	8.70%
2025-12-31	8.51%
2025-09-30	9.18%
2025-06-30	10.17%
2025-03-31	10.18%
2024-12-31	10.89%
2024-09-30	11.23%
2024-06-30	11.81%
2024-03-31	12.49%
2023-12-31	13.59%
2023-09-30	14.51%
2023-06-30	14.89%
2023-03-31	16.16%
2022-12-31	17.58%
2022-09-30	23.16%
2022-06-30	26.26%
2022-03-31	33.94%
2021-12-31	36.03%
2021-09-30	32.56%
2021-06-30	32.30%
2021-03-31	24.97%
2020-12-31	22.80%
2020-09-30	20.38%
2020-06-30	20.83%
2020-03-31	15.84%
2019-12-31	15.15%
2019-09-30	17.90%
2019-06-30	18.56%
2019-03-31	20.83%
2018-12-31	23.57%
2018-09-30	18.54%
2018-06-30	17.88%
2018-03-31	17.49%
2017-12-31	15.72%
2017-09-30	17.10%
2017-06-30	16.56%
2017-03-31	14.80%
2016-12-31	15.36%
2016-09-30	13.32%
2016-06-30	13.86%
2016-03-31	14.78%
2015-12-31	14.35%
2015-09-30	15.68%
2015-06-30	14.91%
2015-03-31	14.23%
2014-12-31	14.63%
2014-09-30	13.55%
2014-06-30	15.39%
2014-03-31	14.86%
2013-12-31	17.05%
2013-09-30	29.25%
2013-06-30	30.32%
2013-03-31	28.45%
2012-12-31	24.02%
2012-09-30	18.18%
2012-06-30	0.68%
2012-03-31	-11.93%
2011-12-31	-17.46%
2011-09-30	-17.58%
2011-06-30	-13.50%
2011-03-31	-8.98%
2010-12-31	-7.56%
2010-09-30	-15.32%
2010-06-30	-13.87%
2010-03-31	-12.54%
2009-12-31	-11.44%
2009-09-30	-11.03%
2009-06-30	-14.14%
2009-03-31	-15.79%
2008-12-31	-15.36%
2008-09-30	-9.23%
2008-06-30	-11.49%
2008-03-31	-11.45%
2007-12-31	-13.42%
2007-09-30	-28.63%
2007-06-30	-25.56%
2007-03-31	-23.10%
2006-12-31	-19.93%
2006-09-30	-17.31%
2006-06-30	-17.07%
2006-03-31	-17.25%
2005-12-31	-17.54%
2005-09-30	-23.57%
2005-06-30	-15.83%
2005-03-31	-10.56%
2004-12-31	1.29%
2004-09-30	18.93%
2004-06-30	14.74%
2004-03-31	11.10%
2003-12-31	0.00%
2003-09-30	-4.17%
2003-06-30	-7.34%

DATE

RETURN ON INVESTED CAPITAL (ROIC)

2026-06-30

9.19%

2026-03-31

8.70%

2025-12-31

8.51%

2025-09-30

9.18%

2025-06-30

10.17%

2025-03-31

10.18%

2024-12-31

10.89%

2024-09-30

11.23%

2024-06-30

11.81%

2024-03-31

12.49%

2023-12-31

13.59%

2023-09-30

14.51%

2023-06-30

14.89%

2023-03-31

16.16%

2022-12-31

17.58%

2022-09-30

23.16%

2022-06-30

26.26%

2022-03-31

33.94%

2021-12-31

36.03%

2021-09-30

32.56%

2021-06-30

32.30%

2021-03-31

24.97%

2020-12-31

22.80%

2020-09-30

20.38%

2020-06-30

20.83%

2020-03-31

15.84%

2019-12-31

15.15%

2019-09-30

17.90%

2019-06-30

18.56%

2019-03-31

20.83%

2018-12-31

23.57%

2018-09-30

18.54%

2018-06-30

17.88%

2018-03-31

17.49%

2017-12-31

15.72%

2017-09-30

17.10%

2017-06-30

16.56%

2017-03-31

14.80%

2016-12-31

15.36%

2016-09-30

13.32%

2016-06-30

13.86%

2016-03-31

14.78%

2015-12-31

14.35%

2015-09-30

15.68%

2015-06-30

14.91%

2015-03-31

14.23%

2014-12-31

14.63%

2014-09-30

13.55%

2014-06-30

15.39%

2014-03-31

14.86%

2013-12-31

17.05%

2013-09-30

29.25%

2013-06-30

30.32%

2013-03-31

28.45%

2012-12-31

24.02%

2012-09-30

18.18%

2012-06-30

0.68%

2012-03-31

-11.93%

2011-12-31

-17.46%

2011-09-30

-17.58%

2011-06-30

-13.50%

2011-03-31

-8.98%

2010-12-31

-7.56%

2010-09-30

-15.32%

2010-06-30

-13.87%

2010-03-31

-12.54%

2009-12-31

-11.44%

2009-09-30

-11.03%

2009-06-30

-14.14%

2009-03-31

-15.79%

2008-12-31

-15.36%

2008-09-30

-9.23%

2008-06-30

-11.49%

2008-03-31

-11.45%

2007-12-31

-13.42%

2007-09-30

-28.63%

2007-06-30

-25.56%

2007-03-31

-23.10%

2006-12-31

-19.93%

2006-09-30

-17.31%

2006-06-30

-17.07%

2006-03-31

-17.25%

2005-12-31

-17.54%

2005-09-30

-23.57%

2005-06-30

-15.83%

2005-03-31

-10.56%

2004-12-31

1.29%

2004-09-30

18.93%

2004-06-30

14.74%

2004-03-31

11.10%

2003-12-31

0.00%

2003-09-30

-4.17%

2003-06-30

-7.34%

Return on Invested Capital (ROIC): 9.19%

REGN Return on Invested Capital (ROIC)

REGN Average Return on Invested Capital (ROIC) Chart

REGN Current vs Average Return on Invested Capital (ROIC) Chart

REGN Return on Invested Capital (ROIC) Metrics

REGN Competitors' Return on Invested Capital (ROIC)

Capital Efficiency

Return on Invested Capital (ROIC) Formula & Definition

Return on Invested Capital (ROIC) FAQ

REGN Return on Invested Capital (ROIC) History

Related Metrics